Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02852655
Title A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma
Recruitment Recruiting
Gender both
Phase Phase 0
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

glioblastoma

gliosarcoma

high grade glioma

Therapies

Pembrolizumab

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
University of California, Los Angeles Active, not recruiting Los Angeles California 90095 United States Details
University of California, San Francisco Active, not recruiting San Francisco California 94143-0372 United States Details
Massachusetts General Hospital Recruiting Boston Massachusetts 02114 United States Details
Dana Farber Cancer Institute Recruiting Boston Massachusetts 02115 United States Details
Memorial Sloan-Kettering Cancer Active, not recruiting New York New York 10065 United States Details
UT, MD Anderson Cancer Center Active, not recruiting Houston Texas 77030 United States Details
Huntsman Cancer Institute Active, not recruiting Salt Lake City Utah 84112 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field